Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Statistics Report: Global Chronic Respiratory Diseases Treatment Market Size & Share to Surpass USD 300 Billion by 2028, Predicts Zion Market Research | Industry Trends, Growth, Value, Segmentation Analysis & Forecast by ZMR

This image opens in the lightbox

News provided by

Zion Market Research

26 Jul, 2022, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, July 26, 2022 /PRNewswire/ -- As per Zion Market Research study, The global chronic respiratory diseases treatment market size was worth around USD 143 billion in 2021 and is predicted to grow to around USD 300 billion by 2028 with a compound annual growth rate (CAGR) of roughly 17.5% between 2022 and 2028.

Chronic Respiratory Diseases Treatment Market: Overview

Chronic respiratory diseases (CRDs) are medical conditions that affect structures of the lungs including airways. The most common CRDs are asthma, pulmonary hypertension, and chronic obstructive pulmonary disease (COPD). The disease is caused by factors like air pollution, chain-smoking, occupational hazards like working with chemicals or around dust, and lower but frequent respiratory infections during young age. Even though chronic respiratory diseases cannot be cured, with the help of medical advancements, various effective medical treatments are available that can help patients live normal lives by properly navigating through the diseases. These treatments help clear the air passages thus managing breathlessness.

The global market cap size is affected by two of the most common forms of CRDs namely asthma and COPD since both of these medical conditions affect the lungs' airways. Asthma involves frequent breathlessness or wheezing attacks occurring due to the narrowing of the airway. The attacks may vary in severity and frequency and each patient has to be carefully treated. The symptoms may increase during physically strenuous activities or nighttime. Children are most prone to asthma. COPD affects only adults and the symptoms may worsen with age and are characterized by chronic cough, breathlessness, and sputum production.

Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): https://www.zionmarketresearch.com/sample/chronic-respiratory-diseases-treatment-market

Our Free Sample Report Includes:

  • 2022 Updated Report Introduction, Overview, and In-depth industry analysis
  • COVID-19 Pandemic Outbreak Impact Analysis Included
  • 205 + Pages Research Report (Inclusion of Updated Research)
  • Provide Chapter-wise guidance on Request
  • 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
  • Includes an Updated List of tables & figures
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
  • Zion Market Research methodology

Key Industry Insights & Findings of the Chronic Respiratory Diseases Treatment Market Reports:

  • As per the analysis shared by our research analyst, the Chronic Respiratory Diseases Treatment Market is expected to grow annually at a CAGR of around 17.5 % (2022-2028).
  • Through the primary research, it was established that the Chronic Respiratory Diseases Treatment Market was valued at approximately USD 143 Billion in 2021 and is projected to reach roughly USD 300 Billion by 2028.
  • The global chronic respiratory diseases treatment market cap size may be dominated by North America during the next few years owing to favorable medical reimbursements policies in regions like the USA and Canada.
  • The rising awareness amongst the general population about CRDs and their treatment is expected to aid regional growth. The rising trend of the emergence of domestic players may also assist in regional expansion.
  • The level of air pollution in these regions is increasing every year due to infrastructural growth propelling the number of patients suffering from respiratory disorders thus aiding the regional market growth.
  • As per World Health Organization (WHO) statistics, there are currently more than 292 million people who suffer from asthma, the most common form of chronic respiratory disease. In 2019, the number of patients was 260 million and caused over 4.5 lakhs deaths.

Zion Market Research published the latest report titled "Global Chronic Respiratory Diseases Treatment Market By Drug Classification (Generic Drugs and Branded Drugs), By Type (Cough & Cold Preparations, Anti-Asthmatics, and COPD Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Drug Stores), By Mode Of Purchase (Over-The-Counter Drugs and Prescription-Based Drugs), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028." into their research database.

Industry Dynamics:

Chronic Respiratory Diseases Treatment Market: Growth Drivers

  • Growing number of chronic respiratory diseases treatment to propel global market growth.

The global chronic respiratory diseases treatment market size may grow owing to the increasing number of patients suffering from CRD across the globe. As per World Health Organization (WHO) statistics, there are currently more than 292 million people who suffer from asthma, the most common form of chronic respiratory disease. In 2019, the number of patients was 260 million and caused over 4.5 lakhs deaths. About 44.3% of asthmatic children below 18 years of age reported having frequent asthma-related attacks in 2019. The number is increasing every year and may propel the global market growth during the forecast period.

As per reports submitted by the Centers for Diseases Control and Prevention, COPD is one of the top 5 leading causes of death in the USA. These diseases are rising owing to increased air pollution, rising smoking habits, and other changing lifestyle trends. The poor air quality is a result of growth in mining activities, urbanization & modernization of cities, increased use of fuel for vehicles & transportation purposes, wildfires, dust, mold spores, and pollen. The growing population is a major contributor to the rise in air impurities resulting in harmful effects on human health and causing multiple respiratory disorders. The global market growth may benefit from these aspects during the forecast period.

Chronic Respiratory Diseases Treatment Market: Restraints

  • Absence of medical plans to completely treat CDRs to restrain global market expansion.

Even with all the technological advancements, no cure can eliminate chronic respiratory diseases. There are medical devices to help patients live by handling the symptoms of respiratory disorders, however, the healthcare sector does not have a medical plan to treat the disorders completely. The patients have to be dependent on the medicines or devices throughout their lifetime thus restricting the global market cap size.

The global market growth may also suffer owing to the side effects that CRD treating drugs have on the patient. These side effects may include dizziness, runny nose, scratchy throat, tremors, or upset stomach resulting in hesitancy amongst patients to adopt medicines for treating CRDs.   

Directly Purchase a Copy of the Report @ https://www.zionmarketresearch.com/buynow/su/chronic-respiratory-diseases-treatment-market

Chronic Respiratory Diseases Treatment Market: Opportunities

  • Advancement in customized drugs to provide lucrative growth opportunities in the global market

The global market is witnessing a rising trend of pharmaceutical companies offering customized treatment plans for chronic respiratory diseases. These plans are also known as precision medicine and are manufactured keeping the individual patient characteristics or symptoms in view. Since every patient suffering from CRD patients may have a different severity level or frequency of the symptoms, their medicinal requirements also differ accordingly. Companies like PTC Therapeutics, GSK, and AstraZeneca have invested in the development of drugs to treat respiratory mutations.

Chronic Respiratory Diseases Treatment Market: Challenges

  • Patent expiration to cause challenges in global market growth

The pharmaceutical companies invest a large number of monetary & non-monetary resources during the drug development phase. During the time, the companies have the patents for the drug, they are solely responsible for its production and manufacturing. However, once the patent expires, generic medicine manufacturers end up utilizing the formula and manufacturing their version of the medicines resulting in heavy losses to the original pharmaceutical manufacturer and creating a challenging situation for the growth of the global market cap.

Global Chronic Respiratory Diseases Treatment Market: Segmentation

  • The global chronic respiratory diseases treatment market is segmented based on drug classification, type, distribution channel, mode of purchase, and region

By drug classification, the global market segments are generic drugs and branded drugs. Both the drug types are claimed to be effective in treating the virus since the underlying active ingredient is the same, and both forms of the drug have to undergo the same Food and Drug Administration approval process. However, as per FDA, generic drugs cost 80 to 85% less than their branded counterparts.

By type, the global market segments are cough & cold preparations, anti-asthmatics, and COPD drugs. The growing number of asthmatic patients has propelled the growth of the anti-asthmatics segments. As per the Asthma & Allergy Foundation of America, over 25 million of the US population suffer from asthma which is the equivalent of 1 in every 13 citizens.

By distribution channel, the global market segments are retail pharmacies, hospital pharmacies, and drug stores. The global market was dominated by hospital pharmacies in the last few years. Since hospital pharmacies generate 30 to 40% of the total hospital revenue, patients are encouraged to purchase from them.

By mode of purchase, over-the-counter drugs, and prescription-based drugs are the two main segments. Since respiratory disease treatment medication can have severe side effects, their sale is generally propelled by prescription-based drugs. Prescription-based drugs generate revenues in USD trillions whereas OTC drugs generate revenues in USD billions.

Get More Insight before Buying@: https://www.zionmarketresearch.com/inquiry/chronic-respiratory-diseases-treatment-market

List of Key Players in Chronic Respiratory Diseases Treatment Market:

  • AstraZeneca plc
  • Merck & Co.Inc.
  • Boehringer Ingelheim Pharmaceuticals Inc
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Ltd.
  • Mylan N.V.
  • Sumitomo Dainippon Pharma Co.Ltd.

Key questions answered in this report:

  • What are the growth rate forecast and market size for Chronic Respiratory Diseases Treatment Market?
  • What are the key driving factors propelling the Chronic Respiratory Diseases Treatment Market forward?
  • What are the most important companies in the Chronic Respiratory Diseases Treatment Market Industry?
  • What segments does the Chronic Respiratory Diseases Treatment Market cover?
  • How can I receive a free copy of the Chronic Respiratory Diseases Treatment Market sample report and company profiles?

Report Scope:

Report Attribute

Details

Market size value in 2021

USD 143 Billion

Revenue forecast in 2028

USD 300 Billion

Growth Rate

CAGR of almost 17.5 % 2022-2028

Base Year

2020

Historic Years

2016 – 2021

Forecast Years

2022 – 2028

Segments Covered

By Product Type, By Application, And By End Use

Forecast Units

Value (USD Billion), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2022 to 2028

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others

Companies Covered

AstraZeneca plc, Merck & Co., Inc., Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline plc, Teva Pharmaceutical Ltd., Mylan N.V., and Sumitomo Dainippon Pharma Co., Ltd.

Report Coverage

Market growth drivers, restraints, opportunities, Porter's five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.

Customization Scope

Avail of customized purchase options to meet your exact research needs.  

https://www.zionmarketresearch.com/custom/2130

 Free Brochure: https://www.zionmarketresearch.com/requestbrochure/chronic-respiratory-diseases-treatment-market

Recent Developments

  • In October 2020, Zydus Cadila launched a new product for the Indian market of COPD patients. The product is called Forglyn pMDI and is claimed to be India's first pressurized Metered Dose Inhaler which is priced at Rs 495 per pack and is made in India. With this new product, the company aims to bring next-generation respiratory-related therapies.
  • In September 2021, Global Allergy and Airways Patient Platform (GAAPP), The European Respiratory Society (ERS), Amgen, and AstraZeneca launched the International Respiratory Coalition, a new partnership to transform respiratory healthcare post-Covid-19. The new partnership will provide the necessary support to healthcare systems and governments to recover from the impacts of Covid-19 in the respiratory sector.

Regional Dominance:

  • North America to lead global market growth during the projection period

The global chronic respiratory diseases treatment market cap size may be dominated by North America during the next few years owing to favorable medical reimbursements policies in regions like the USA and Canada. The rising awareness amongst the general population about CRDs and their treatment is expected to aid regional growth. The rising trend of the emergence of domestic players may also assist in regional expansion.

Asia-Pacific is expected to register high CAGR due to the growing population and medical cases in regions like China, India, and South Korea. The level of air pollution in these regions is increasing every year due to infrastructural growth propelling the number of patients suffering from respiratory disorders thus aiding the regional market growth. Asia-Pacific is witnessing high investment from foreign companies in the pharmaceutical sector because of the presence of favorable government policies along with skilled and effective labor.

Global Chronic Respiratory Diseases Treatment Market is segmented as follows:

Chronic Respiratory Diseases Treatment Market: By Drug Classification Outlook (2022-2028)

  • Generic Drugs
  • Branded Drugs

Chronic Respiratory Diseases Treatment Market: By Type Outlook (2022-2028)

  • Cough & Cold Preparations
  • Anti-Asthmatics
  • COPD Drugs

Chronic Respiratory Diseases Treatment Market: By Distribution Channel Outlook (2022-2028)

  • Retail Pharmacies
  • Hospital Pharmacies
  • Drug Stores

Chronic Respiratory Diseases Treatment Market: By Mode of Purchase Outlook (2022-2028)

  • Over-The-Counter Drugs
  • Prescription-Based Drugs

Chronic Respiratory Diseases Treatment Market: By Region Outlook (2022-2028)

North America

  • The U.S.
  • Canada

Europe

  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Press Release For Chronic Respiratory Diseases Treatment Market: https://www.zionmarketresearch.com/news/global-chronic-respiratory-diseases-treatment-market

Browse Other Related Research Reports from Zion Market Research

  • Healthcare E-Commerce Market - Global Industry Analysis: The global Healthcare E-Commerce Market accrued earnings worth approximately 353.1 (USD Billion) in 2020 and is predicted to gain revenue of about 840.1 (USD Billion) by 2028, is set to record a CAGR of nearly 17.1% over the period from 2021 to 2028.
  • Immuno-Oncology Clinical Trials Market - Global Industry Analysis: The global Immuno-Oncology Clinical Trials Market accrued earnings worth approximately 5.4 (USD Billion) in 2020 and is predicted to gain revenue of about 15.6 (USD Billion) by 2028, is set to record a CAGR of nearly 13.7% over the period from 2021 to 2028.
  • Pleural Effusions Treatment Market - Global Industry Analysis: The global pleural effusions treatment market size was worth around USD 4.4 billion in 2021 and is predicted to grow to around USD 6.8 billion by 2028 with a compound annual growth rate (CAGR) of roughly 6.4% between 2022 and 2028.

Browse through Zion Market Research's coverage of the Global Healthcare Industry

Follow Us on LinkedIn | Twitter | Facebook

About Us

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country report. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us: 
Zion Market Research 
244 Fifth Avenue, Suite N202 
New York, 10001, United States 
Tel: +49-322 210 92714 
USA/Canada Toll-Free No.1-855-465-4651 
Email: sales@zionmarketresearch.com 
Website: https://www.zionmarketresearch.com/ 
Blog: https://techpru.com/ | http://thehealthypandas.com/ | https://www.custommarketinsights.com/

Logo: https://mma.prnewswire.com/media/1605489/Zion_Market_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.